Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $135.47 million
- Book Value:
- Revenue TTM:
- $73.36 million
- Operating Margin TTM:
- Gross Profit TTM:
- $67.01 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
OptiNose had its IPO on 2017-10-13 under the ticker symbol OPTN.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. OptiNose has a staff strength of 141 employees.
Shares of OptiNose opened at $1.22 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $1.18 - $1.25, and closed at $1.21.
This is a -3.2% slip from the previous day's closing price.
A total volume of 547,800 shares were traded at the close of the day’s session.
In the last one week, shares of OptiNose have slipped by -10.37%.
OptiNose's Key Ratios
OptiNose has a market cap of $135.47 million, indicating a price to book ratio of 24.2559 and a price to sales ratio of 2.4666.
In the last 12-months OptiNose’s revenue was $73.36 million with a gross profit of $67.01 million and an EBITDA of $-48384000. The EBITDA ratio measures OptiNose's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, OptiNose’s operating margin was -66.61% while its return on assets stood at -24.56% with a return of equity of -1050.5%.
In Q1, OptiNose’s quarterly earnings growth was a positive 0% while revenue growth was a negative 19.7%.
OptiNose’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into OptiNose’s profitability.
OptiNose stock is trading at a EV to sales ratio of 3.3414 and a EV to EBITDA ratio of -4.4618. Its price to sales ratio in the trailing 12-months stood at 2.4666.
OptiNose stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $114.93 million
- Total Liabilities
- $166.30 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
OptiNose ended 2023 with $114.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $114.93 million while shareholder equity stood at $-73785000.00.
OptiNose ended 2023 with $0 in deferred long-term liabilities, $166.30 million in other current liabilities, 112000.00 in common stock, $-703740000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $83.93 million and cash and short-term investments were $83.93 million. The company’s total short-term debt was $130,623,000 while long-term debt stood at $0.
OptiNose’s total current assets stands at $83.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $16.98 million compared to accounts payable of $6.24 million and inventory worth $8.30 million.
In 2023, OptiNose's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, OptiNose paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
OptiNose stock is currently trading at $1.21 per share. It touched a 52-week high of $4.3 and a 52-week low of $4.3. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $1.77 and 200-day moving average was $2.31 The short ratio stood at 14.95 indicating a short percent outstanding of 0%.
Around 750.1% of the company’s stock are held by insiders while 7752.7% are held by institutions.
Frequently Asked Questions About OptiNose
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.